Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Therapeutic compounds comprised of anti-fc receptor binding agents

A receptor and antibody technology, applied in antibody medical components, antibody mimics/scaffolds, antibodies, etc.

Inactive Publication Date: 2007-12-26
ER SQUIBB & SONS INC
View PDF20 Cites 2 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, the use of murine monoclonal antibodies in some human therapies can lead to the development of an immune response to the "foreign murine protein"

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Therapeutic compounds comprised of anti-fc receptor binding agents
  • Therapeutic compounds comprised of anti-fc receptor binding agents
  • Therapeutic compounds comprised of anti-fc receptor binding agents

Examples

Experimental program
Comparison scheme
Effect test

example 1

[0085] example 1 : Production of bispecific antibodies comprising murine or humanized antibodies specific for Fc receptors and anti-her2 neu antibodies

[0086] Monoclonal antibodies

[0087] Anti-FcγRI monoclonal antibodies (mAbs), M22, M32.2, and 197 were purified from hybridoma supernatants by ion-exchange chromatography, and from hybridomas by protein A affinity chromatography (Pharmacia, Piscataway, NJ) and gel filtration. DZ33, a human anti-HIV-1 IgGl mAb, was purified from tumor supernatants. M32.2 was deposited with the American Type Culture Collection (12301 Parklawn Drive, Rockville, MD20852) on July 1, 1987, and the determined ATCC accession number is HB9469.

[0088] cell line

[0089] Murine myeloma NSO (ECACC85110503) is a non-Ig synthetic cell line that was used to express recombinant mAbs. NSO cells were cultured in DMEM supplemented with 10% fetal bovine serum (FBS, Gibco, Paisley, U.K.). SKBR-3 is a human breast cancer cell line that overexpresses t...

example 2

[0136] Example 2 : Generation of functional H22-epidermal growth factor fusion protein

[0137] Materials and methods

[0138] Expression Vectors and Cloning

[0139]Expression vectors (pSVgpt and pSVhygt) for genomic cloning of the heavy and light chains of H22 are disclosed in WO 94 / 10332 entitled "Humanized Antibodies to FcReceptors for Immunoglobulin G on Human Mononuclear Phagocytes". For Fab-ligand fusion constructs, no changes to the light chain are required. However, for the heavy chain, it is necessary to remove the CH2 and CH3 regions and replace them with the coding sequence for the ligand. The heavy chain vector carries two BamHI sites, one in the intron between VH and CH1 and the other downstream of CH3. Using the BamHI restriction site described above, the DNA encoding the constant region was replaced with a truncated version encoding only CH1 and most of the hinge region. To this end, the polymerase chain reaction (PCR) was used to generate a new C-ter...

example 3

[0163] Example 3: H22-Heregulin (H22-gp30) fusion protein mediates tumor cell death

[0164]Heregulin (HRG) is a ligand for HER3 and HER4 molecules. Both receptors form heterodimers with HER2, a molecule overexpressed by certain breast cancer cells. The affinity of HRG for HER3 and HER4 is significantly increased when the molecule is derived from a heterodimer with HER2. This example demonstrates that bispecific molecules comprising heregulin and a binding specificity for FcγRI inhibit the growth of tumor cell lines and mediate fusion protein-dependent fusion of these cells in the presence of FcγRI-bearing cytotoxic effector cells. sex cytotoxicity.

[0165] The H22-heregulin fusion protein was constructed in the same manner as the H22-EGF fusion protein described in Example 2. Briefly, the genomic DNA encoding the Fd fragment of the humanized anti-FcyRI mAb, H22, was fused to the cDNA encoding the EGF region of β2-type HRG. The amino acid sequence of the H22-HRG fusion pr...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
molecular weightaaaaaaaaaa
Login to View More

Abstract

Multispecific multivalent molecules which are specific to an Fc receptor (FcR), and therapeutic uses and methods for making the molecules are described.

Description

[0001] This application is a Chinese patent application (national application number is No.96196166.X, international application number is PCT / US96 / 09988) divisional application. Background technique [0002] Immunoglobulins (Igs) consist of two heavy chains and two light chains, each containing NH that determine antibody and effector gene function 2 - terminal antigen binding variable region and COOH - terminal constant region. The COOH-terminal region of the Ig heavy chain forms the Fc region and participates in eliciting cellular activity through interactions with specific receptors called Fc receptors (FcRs). Fc receptors for all Ig classes or isotypes such as IgG (FcγR), IgE (FcεR), IgA (FcαR), IgM (FcμR), and IgD (FcδR) have been identified. The different biology of antibodies of different isotypes Activity depends in part on its ability to bind to different FcRs expressed on different immune (effector) cells (Fridman, W.H. (1991, September), The FASEB Journal Vol.5, ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): C07K14/33C07K14/485C07K16/28C07K16/30C07K16/32A61K39/395A61P35/00A61P37/02A61K38/00C12N15/09A61K39/00A61P37/00C07K14/725C07K16/46C07K19/00C12N15/02C12P21/08
CPCC07K16/2863C07K2319/00C07K16/32C07K16/3007C07K14/485C07K2317/732C07K14/33A61K38/00C07K16/283C07K2317/73C07K2317/24A61P35/00A61P37/00A61P37/02C07K16/46A61K39/395
Inventor Y·M·德奥J·高尔斯丁R·格拉兹尔诺C·索马孙达拉姆
Owner ER SQUIBB & SONS INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com